EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
10 avr. 2023 08h00 HE
|
EDAP TMS S.A.
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Webcast scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023 -- EDAP...
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
06 avr. 2023 08h00 HE
|
EDAP TMS S.A.
Allows for market launch of the only micro-ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in...
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
30 mars 2023 06h30 HE
|
EDAP TMS S.A.
Record full-year 2022 total revenue of EUR 55.1 million ($58.0 million) increased 25.1% over full-year 2021Full-year HIFU revenue was EUR 15.6 million (USD 16.4 million), an increase of 57.7% as...
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
21 mars 2023 16h30 HE
|
EDAP TMS S.A.
Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP) The HIFU...
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
09 mars 2023 08h00 HE
|
EDAP TMS S.A.
LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the...
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
14 févr. 2023 09h00 HE
|
EDAP TMS S.A.
Record full-year 2022 total preliminary unaudited revenue of €55.1 million ($58.0 million) represents an increase of 25.1% over full-year 2021, driven by 58.1% HIFU growth Record Q4 2022 total...
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
31 janv. 2023 08h00 HE
|
EDAP TMS S.A.
Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL)Positive safety profile with 96.7% of patients with no or non-significant adverse...
EDAP Announces Record Q4 US Focal One Placements
05 janv. 2023 08h00 HE
|
EDAP TMS S.A.
Company preliminarily reports nine Focal One Placements in the U.S., including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in...
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
06 déc. 2022 08h00 HE
|
EDAP TMS S.A.
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment...
EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis
30 nov. 2022 16h01 HE
|
EDAP TMS S.A.
Study to begin enrolling patients in Q2 2023 Endometriosis represents significant expansion opportunity for Focal One LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP)...